Summary
Industry
Insights
Kuano, based in London, offers a quantum simulation platform aimed at transforming drug discovery for biotech and health tech companies. Their B2B, SaaS model provides faster and more accurate simulations compared to traditional methods, potentially reducing timelines and costs. Supported by investors like Ascension Ventures and ACF Investors, Kuano leverages quantum computing to offer a competitive edge in a market dominated by longer, costlier processes. If successful, Kuano could significantly impact the development of new drugs.